NeuroSense Therapeutics Stock (NASDAQ:NRSN)
Previous Close
$1.15
52W Range
$0.80 - $2.60
50D Avg
$1.51
200D Avg
$1.32
Market Cap
$30.01M
Avg Vol (3M)
$670.37K
Beta
1.57
Div Yield
-
NRSN Company Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.